Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: Protocol of a randomized controlled trial [ISRCTN43532635]

BMC Health Services Research

Volumn 4, Issue , 2004, Pages 1-9

  Doupe, Malcolm ^a,b   Katz, Alan ^a,b   Kvern, Brent ^b   Manness, Lori Jean ^c   Metge, Colleen ^b   Thomson, Glen T D ^d   Morrison, Laura ^a   Rother, Kat ^a  

^a St Boniface Research Centre   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d Ctr Inflammatory Arthritic Dis S   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CANADA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE POLICY; HUMAN; MEDICAL AUDIT; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL PRACTICE; MONOTHERAPY; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STOMACH PROTECTION; CHRONIC DISEASE; DRUG USE; EDUCATION; FEEDBACK SYSTEM; GENERAL PRACTITIONER; HEALTH SERVICE; INFLAMMATION; OUTCOME ASSESSMENT; PAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; CYCLOOXYGENASE INHIBITORS; DRUG UTILIZATION REVIEW; EDUCATION, MEDICAL, CONTINUING; FEEDBACK; GASTROINTESTINAL AGENTS; GUIDELINE ADHERENCE; HEALTH SERVICES MISUSE; HUMANS; INFLAMMATION; MANITOBA; MEDICAL AUDIT; OUTCOME ASSESSMENT (HEALTH CARE); PAIN; PHYSICIANS, FAMILY;

EID: 4544249437     PISSN: 14726963     EISSN: None     Source Type: Journal    
DOI: 10.1186/1472-6963-4-21     Document Type: Article

References (44)

1. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999, 340:1888-1899. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2] [3]
2. Laine L: Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003, 25:S32-S40. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-8,2. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2]
4. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2] [3]
5. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2]
6. Singh G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998, 105:31S-38S. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1] [2]
7. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J: Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001, 52:185-192. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
8. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J: Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000, 43:917-924. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1]
9. Bloom BS: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988, 84:20-24. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1]
10. Chevat C, Pena BM, Al MJ, Rutten FF: Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective. Pharmacoeconomics 2001, 19(Suppl 1):17-32. [PubMed Abstract] Return to citation in text: [1]
11. Herings RM, Klungel OH: An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001, 19:655-665. [PubMed Abstract] Return to citation in text: [1]
12. Sturkenboom MC, Romano F, Simon G, Correa-Leite ML, Villa M, Nicolosi A, et al.: The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum 2002, 47:132-140. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
13. Hawkey CJ: Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol Suppl 1996, 220:124-127. [PubMed Abstract] Return to citation in text: [1]
14. Maetzel A, Krahn M, Naglie G: The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003, 49:283-292. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2]
15. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, et al.: Controversies in COX-2 selective inhibition. J Rheumatol 2002, 29:1501-1510. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
16. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954-959. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
17. Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
18. Tannenbaum H, Peloso PM, Russell AS, Marlow B: An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference. Can J Clin Pharmacol 2000, 7(Suppl A):4A-16A. [PubMed Abstract] Return to citation in text: [1] [2] [3] [4] [5]
19. National Institute for Clinical Excellence: Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. [http://www.nice.org. uk/pdf/coxiifullguidance.pdf] Technology Appraisal Guidance 2001, 27:1-14. Return to citation in text: [1] [2] [3] [4]
20. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum 2000, 43:1905-1915. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1] [2] [3] [4]
21. Guidelines for the management of rheumatoid arthritis: 2002 Update Arthritis Rheum 2002, 46:328-346. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1] [2] [3] [4]
22. Manitoba Health: Prescription Drugs Cost Assistance Act Regulation (Parts 1 and 2). [http://www.gov.mb.ca/health/mdbif/] 2003. Return to citation in text: [1] [2] [3] [4] [5]
23. Ministry of Health: Ontario Drug Benefit Formulary / Comparative Drug Index Edition no. 38. [http://www.health.gov.on.ca/english/providers/program/ drugs/odbf_mn.html] 2003. Return to citation in text: [1]
24. VHA Pharmacy Benefits Management Strategic Health Care Group and the Medical Advisory Panel: Summary of the criteria for non-formulary use of Cyclooxygenase 2 (COX-II) inhibitors in high-risk veteran patients. [http://www.vapbm.org/criteria/coxcriteria.pdf] 2001. Return to citation in text: [1]
25. Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
26. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796. [PubMed Abstract] Return to citation in text: [1]
27. Schwappach DL, Koeck CM: Selective COX-2 inhibitors: a health economic perspective. Wien Med Wochenschr 2003, 153:116-122. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
28. Spiegel BM, Targownik L, Dulai GS, Gralnek IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138:795-806. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
29. Maetzel A, Ferraz MB, Bombardier C: The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998, 41:16-25. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1]
30. Lomas J: Words without action? The production, dissemination, and impact of consensus recommendations. Annu Rev Public Health 1991, 12:41-65. [PubMed Abstract] [Publisher Full Text] Return to citation in text: [1]
31. Oxman AD, Thomson MA, Davis DA, Haynes RB: No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995, 153:1423-1431. [PubMed Abstract] Return to citation in text: [1]
32. Davis DA, Taylor-Vaisey A: Translating guidelines into practice. A systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997, 157:408-416. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
33. Grimshaw JM, Shirran L, Thomas R, Mowatt G, Fraser C, Bero L, et al.: Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001, 39:II2-45. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
34. Cutts C, LaCaze A: Nonsteroidal anti-inflammatory drugs and potential risks in a convenience sample of general practitioners. Aust Fam Physician 2002, 31:590-592. [PubMed Abstract] Return to citation in text: [1]
35. Cox E: The Drug of Choice Among Boomers - Cox-2 Inhibitors: Here's What You May Not Know. [http://www.express-scripts.com/other/news_views/outcomes2002/ outcomes_conf_2002_pres_summaries.htm] 2002. Return to citation in text: [1]
36. Mamdani M, Rochon P, Laupacis A, Anderson G: Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ 2002, 167:1125-1126. [PubMed Abstract][Publisher Full Text][PubMed Central Full Text] Return to citation in text: [1]
37. Marra CA, Esdaile JM, Sun H, Anis AH: The cost of COX inhibitors: how selective should we be? J Rheumatol 2000, 27:2731-2733. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
38. Landsberg PG, Pillans PI, Radford JM: Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital. Intern Med J 2003, 33:225-228. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
39. Cullen DJ, Seager JM, Holmes S, Doherty M, Wilson JV, Garrud P, et al.: Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000, 14:177-185. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
40. Davis P, Hughes S, Low S, Sholter D, Homik J, Juby A, et al.: Clinical Scenarios in Osteoarthritis: Interactive Problem-Based Case Studies. 2000. Prepared by the Division of Continuing Medical Education, Faculty of Medicine and Dentistry, University of Alberta, in Edmonton, in partnership with Patient Health - CME Merck Frosst Canada & Co. Return to citation in text: [1]
41. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD: Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2003, CD000259. [PubMed Abstract] Return to citation in text: [1]
42. Richards D, Toop L, Graham P: Do clinical practice education groups result in sustained change in GP prescribing? Fam Pract 2003, 20:199-206. [PubMed Abstract][Publisher Full Text] Return to citation in text: [1]
43. Thomson O'Brien MA, Freemantle N, Oxman AD, Wolf F, Davis DA, Herrin J: Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2001, CD003030. [PubMed Abstract] Return to citation in text: [1]
44. Cohen J: Statistical power analysis 2 Edition Hillsdale: Lawrence Erlbaum Associates, Inc 1988. Return to citation in text: [1]